Immunovant to Present at Roivant Investor Day on September 28th
On September 21, 2022, Immunovant (Nasdaq: IMVT) announced that CEO Pete Salzmann will present a corporate update at Roivant’s Investor Day on September 28, 2022, at 11:15 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
On September 21, 2022, Immunovant (Nasdaq: IMVT) announced that CEO Pete Salzmann will present a corporate update at Roivant’s Investor Day on September 28, 2022, at 11:15 AM ET. The event will include a webcast available on the company's website. Immunovant focuses on developing therapies for autoimmune diseases and is known for its investigational compound, batoclimab, a monoclonal antibody targeting FcRn. The company aims to meet significant unmet patient needs in this sector.
Details
News Market Reaction – IMVT
The recorded move for IMVT in the trading session of this news was +3.04%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will present a corporate update at Roivant’s Investor Day, taking place on September 28th, 2022.
| Roivant Investor Day presentation details: | |
| Date: | Wednesday, September 28th, 2022 |
| Time: | 11:15 am Eastern Time |
| Webcast: | The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company’s website, located at www.immunovant.com. |
About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage biopharmaceutical company dedicated to enabling normal lives for people with autoimmune diseases. As a leader in FcRn inhibitor technology, the Company is boldly developing innovative therapies for a range of debilitating autoimmune diseases with significant unmet patient needs. The Company’s investigational compound, batoclimab, is a novel, fully human, monoclonal antibody targeting the neonatal Fc receptor (FcRn). For additional information on the Company, please visit www.immunovant.com.
Contact:
Chau Cheng, PhD, MBA
VP Investor Relations
Immunovant, Inc.
info@immunovant.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.